R292K 取代与流感 A(H7N9)病毒的药物敏感性。
R292K substitution and drug susceptibility of influenza A(H7N9) viruses.
出版信息
Emerg Infect Dis. 2013;19(9):1521-4. doi: 10.3201/eid1909.130724.
Abstract
Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered.
摘要
神经氨酸酶抑制剂是目前唯一获准用于治疗人类感染甲型 H7N9 禽流感病毒的抗病毒药物。根据神经氨酸酶抑制试验，R292K 取代降低了抑制剂（特别是奥司他韦）的抗病毒功效，并降低了病毒在细胞培养中的适应性。应考虑使用 pH 改良的神经氨酸酶抑制试验监测携带 R292K 的病毒的出现。
相似文献
1
R292K substitution and drug susceptibility of influenza A(H7N9) viruses.
Emerg Infect Dis. 2013;19(9):1521-4. doi: 10.3201/eid1909.130724.
2
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
mBio. 2013 Jul 16;4(4):e00396-13. doi: 10.1128/mBio.00396-13.
3
Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019.
Virology. 2020 Oct;549:77-84. doi: 10.1016/j.virol.2020.07.018. Epub 2020 Aug 8.
4
Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
J Virol. 2015 May;89(10):5419-26. doi: 10.1128/JVI.03513-14. Epub 2015 Mar 4.
5
[Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir].
Bing Du Xue Bao. 2014 Jul;30(4):396-401.
6
Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts.
Virol J. 2019 Jul 2;16(1):87. doi: 10.1186/s12985-019-1194-9.
7
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.
Nat Commun. 2013;4:2854. doi: 10.1038/ncomms3854.
8
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Antiviral Res. 2019 Aug;168:68-75. doi: 10.1016/j.antiviral.2019.05.009. Epub 2019 May 25.
9
Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.
J Infect Dis. 2015 Jan 15;211(2):249-57. doi: 10.1093/infdis/jiu447. Epub 2014 Aug 14.
10
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
Sci Rep. 2013 Dec 20;3:3561. doi: 10.1038/srep03561.
引用本文的文献
1
Influenza neuraminidase mutations and resistance to neuraminidase inhibitors.
Emerg Microbes Infect. 2024 Dec;13(1):2429627. doi: 10.1080/22221751.2024.2429627. Epub 2024 Nov 26.
2
Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt.
Arch Virol. 2024 Apr 9;169(5):95. doi: 10.1007/s00705-024-06022-6.
3
Highly Pathogenic Avian Influenza A(H5N1) Virus Clade 2.3.4.4b in Wild Birds and Live Bird Markets, Egypt.
Pathogens. 2022 Dec 26;12(1):36. doi: 10.3390/pathogens12010036.
4
Phylogeography and Biological Characterizations of H12 Influenza A Viruses.
Viruses. 2022 Oct 13;14(10):2251. doi: 10.3390/v14102251.
5
Detection of a Novel Reassortant H9N9 Avian Influenza Virus in Free-Range Ducks in Bangladesh.
Viruses. 2021 Nov 24;13(12):2357. doi: 10.3390/v13122357.
6
Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
Antiviral Res. 2020 Oct;182:104886. doi: 10.1016/j.antiviral.2020.104886. Epub 2020 Aug 1.
7
H7N9 Influenza Virus in China.
Cold Spring Harb Perspect Med. 2021 Aug 2;11(8):a038349. doi: 10.1101/cshperspect.a038349.
8
Antivirals Targeting the Neuraminidase.
Cold Spring Harb Perspect Med. 2022 Jan 4;12(1):a038455. doi: 10.1101/cshperspect.a038455.
9
Inventory of molecular markers affecting biological characteristics of avian influenza A viruses.
Virus Genes. 2019 Dec;55(6):739-768. doi: 10.1007/s11262-019-01700-z. Epub 2019 Aug 19.
10
A Single Amino Acid Substitution at Residue 218 of Hemagglutinin Improves the Growth of Influenza A(H7N9) Candidate Vaccine Viruses.
J Virol. 2019 Sep 12;93(19). doi: 10.1128/JVI.00570-19. Print 2019 Oct 1.
本文引用的文献
1
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.
Lancet. 2013 Jun 29;381(9885):2273-9. doi: 10.1016/S0140-6736(13)61125-3. Epub 2013 May 29.
2
Emergence of avian influenza A(H7N9) virus causing severe human illness - China, February-April 2013.
MMWR Morb Mortal Wkly Rep. 2013 May 10;62(18):366-71.
3
Human infection with a novel avian-origin influenza A (H7N9) virus.
N Engl J Med. 2013 May 16;368(20):1888-97. doi: 10.1056/NEJMoa1304459. Epub 2013 Apr 11.
4
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.
5
Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012.
Wkly Epidemiol Rec. 2012 Sep 28;87(39):369-74.
6
Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Antivir Ther. 2012;17(1 Pt B):159-73. doi: 10.3851/IMP2067. Epub 2012 Feb 3.
7
Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.
J Virol. 2010 Sep;84(18):9427-38. doi: 10.1128/JVI.00373-10. Epub 2010 Jul 14.
8
Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.
Antiviral Res. 2009 Jan;81(1):16-24. doi: 10.1016/j.antiviral.2008.08.008. Epub 2008 Oct 7.
9
Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets.
Antiviral Res. 2002 May;54(2):99-111. doi: 10.1016/s0166-3542(01)00214-5.
10
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
Antiviral Res. 2002 May;54(2):79-88. doi: 10.1016/s0166-3542(01)00215-7.
Zotero 插件